Edition:
India

Rhythm Pharmaceuticals Inc (RYTM.OQ)

RYTM.OQ on NASDAQ Stock Exchange Global Market

24.41USD
6 Dec 2019
Change (% chg)

$0.54 (+2.26%)
Prev Close
$23.87
Open
$24.04
Day's High
$24.45
Day's Low
$23.78
Volume
65,179
Avg. Vol
92,329
52-wk High
$31.88
52-wk Low
$18.00

Latest Key Developments (Source: Significant Developments)

Rhythm Pharmaceuticals Completes Enrollment Of Pivotal Cohort In Phase 3 Clinical Trial Evaluating Setmelanotide In Bardet-Biedl And Alström Syndromes
Thursday, 5 Dec 2019 

Dec 5 (Reuters) - Rhythm Pharmaceuticals Inc ::RHYTHM PHARMACEUTICALS COMPLETES ENROLLMENT OF PIVOTAL COHORT IN PHASE 3 CLINICAL TRIAL EVALUATING SETMELANOTIDE IN BARDET-BIEDL AND ALSTRÖM SYNDROMES.RHYTHM PHARMACEUTICALS INC - TOPLINE DATA EXPECTED IN Q4 OF 2020 OR EARLY IN Q1 OF 2021.RHYTHM PHARMACEUTICALS INC - SUPPLEMENTAL COHORT CONTINUES ENROLLMENT TO MEET PATIENT DEMAND.  Full Article

Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results
Friday, 1 Nov 2019 

Nov 1 (Reuters) - Rhythm Pharmaceuticals Inc ::RHYTHM PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.04.Q3 EARNINGS PER SHARE ESTIMATE $-1.07 -- REFINITIV IBES DATA.AS OF SEPTEMBER 30, 2019, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $162.4 MILLION.RHYTHM PHARMACEUTICALS SAYS EXPECTS TO REPORT TOPLINE DATA FROM COMBINED PHASE 3 TRIAL EVALUATING SETMELANOTIDE IN BBS AND ALSTRÖM SYNDROME IN 2020.RHYTHM PHARMACEUTICALS - EXPECTS TO SUBMIT AN INVESTIGATIONAL NEW DRUG APPLICATION FOR RM-853 TO FDA IN 2020.RHYTHM PHARMACEUTICALS - ON TRACK TO COMPLETE OUR NEW DRUG APPLICATION SUBMISSION TO U.S. FDA FOR THESE TWO INDICATIONS IN Q4 OF THIS YEAR OR Q1 OF 2020..  Full Article

Rhythm Pharmaceuticals Says Phase 3 Data In Pomc And Leptin Receptor Deficiency Obesity Expected In Q3
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Rhythm Pharmaceuticals Inc ::RHYTHM PHARMACEUTICALS TO OUTLINE EXPECTED 2019 MILESTONES AND REVIEW UPDATED CLINICAL DATA IN BARDET-BIEDL SYNDROME AT 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.RHYTHM PHARMACEUTICALS INC - COMBINED PIVOTAL PHASE 3 CLINICAL TRIAL IN BBS AND ALSTRÖM SYNDROME ON TARGET.RHYTHM PHARMACEUTICALS INC - PHASE 3 CLINICAL TRIALS IN PRO-OPIOMELANOCORTIN (POMC) AND LEPTIN RECEPTOR (LEPR) DEFICIENCY OBESITY FULLY ENROLLED.RHYTHM PHARMACEUTICALS INC - PHASE 3 CLINICAL TRIALS IN POMC AND LEPTIN RECEPTOR DEFICIENCY OBESITY ON TRACK FOR INITIAL DATA ANTICIPATED IN Q3.  Full Article

Orbimed Advisors Cuts Stake In Rhythm Pharma to 8.63 Pct From 10.63 Pct
Tuesday, 5 Jun 2018 

June 4 (Reuters) - Rhythm Pharmaceuticals Inc ::ORBIMED ADVISORS LLC CUTS STAKE IN RHYTHM PHARMACEUTICALS INC 8.63 PERCENT AS OF MAY 31 FROM A STAKE OF 10.63 PERCENT AS OF JAN 24 - SEC FILING.  Full Article

Rhythm Pharmaceuticals Q1 Loss Per Share $0.60
Monday, 14 May 2018 

May 14 (Reuters) - Rhythm Pharmaceuticals Inc ::RHYTHM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.60.AS OF MARCH 31, 2018, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $136.5 MILLION.EXISTING CASH AND CASH EQUIVALENTS, SHORT-TERM INVESTMENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO H2 2019.  Full Article

Rhythm Pharma Announces Licensing Agreement With Takeda
Monday, 2 Apr 2018 

April 2 (Reuters) - Rhythm Pharmaceuticals Inc ::RHYTHM PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PRECLINICAL TREATMENT FOR PRADER-WILLI SYNDROME.RHYTHM PHARMACEUTICALS INC - ‍RHYTHM EXPECTS TO FILE INVESTIGATIONAL NEW DRUG APPLICATION IN Q1 OF 2020​.RHYTHM PHARMACEUTICALS INC - ‍ ACQUIRED EXCLUSIVE, WORLDWIDE RIGHTS FROM TAKEDA TO DEVELOP AND COMMERCIALIZE T-3525770 (NOW RM-853)​.RHYTHM PHARMACEUTICALS INC - ‍UNDER TERMS, CO WILL ASSUME SOLE RESPONSIBILITY FOR GLOBAL PRODUCT DEVELOPMENT AND COMMERCIALIZATION OF RM-853​.RHYTHM PHARMACEUTICALS-‍ TAKEDA TO GET UPFRONT PAYMENT OF $5 MLN IN CO'S STOCK, BACK-END DEVELOPMENT MILESTONES, SINGLE-DIGIT ROYALTIES ON RM-853 SALES​.RHYTHM PHARMACEUTICALS INC - ‍WILL EXPLORE OPPORTUNITIES TO EVALUATE SETMELANOTIDE AND RM-853 IN COMBINATION, AS THERE MAY BE COMPLEMENTARY EFFECTS​​.  Full Article

Rhythm Pharmaceuticals Reports Qtrly Loss Per Share $0.41‍​
Tuesday, 13 Mar 2018 

March 12 (Reuters) - Rhythm Pharmaceuticals Inc ::RHYTHM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.RHYTHM PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.41‍​.RHYTHM - EXPECTS EXISTING CASH & CASH EQUIVALENTS, MARKETABLE SECURITIES SUFFICIENT TO FUND OPERATING EXPENSES, CAPEX REQUIREMENTS INTO H2 2019‍​.  Full Article

WuXi NextCODE Entered Partnership With Rhythm Pharmaceuticals Financial
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - WuXi NextCODE: :WUXI NEXTCODE - ENTERED PARTNERSHIP WITH RHYTHM PHARMACEUTICALS; FINANCIAL TERMS WERE NOT DISCLOSED.  Full Article

Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Rhythm Pharmaceuticals Inc ::RHYTHM PHARMACEUTICALS ANNOUNCES PROGRESS IN CLINICAL DEVELOPMENT OF SETMELANOTIDE FOR TREATMENT OF RARE GENETIC DISORDERS OF OBESITY.RHYTHM PHARMACEUTICALS - SETMELANOTIDE GRANTED ORPHAN DRUG DESIGNATION FOR TREATMENT OF LEPTIN RECEPTOR (LEPR) DEFICIENCY OBESITY.RHYTHM PHARMACEUTICALS - FINALIZED PROTOCOL FOR PIVOTAL PHASE 3 CLINICAL TRIAL IN PRO-OPIOMELANOCORTIN (POMC) DEFICIENCY OBESITY.RHYTHM PHARMACEUTICALS - CONFIRMS PLANS TO FILE NDA WITH FDA BASED ON ONE-YEAR DATA FROM 10 PATIENT COHORT IN POMC PHASE 3 CLINICAL TRIAL.  Full Article